Introduction
Brand name: Vermont M 50/500
Manufacturer: (Assumed to be your company / Astemax‑aligned brand, as per your context)
Composition: Vildagliptin 50 mg + Metformin hydrochloride IP 500 mg tablet
Vermont M 50/500 is a fixed‑dose combination antidiabetic tablet formulated for type 2 diabetes mellitus, combining vildagliptin (a DPP‑4 inhibitor) and metformin (a biguanide) in a single once‑twice‑daily dose.
Key ingredients and mechanism
Vildagliptin 50 mg
A DPP‑4 inhibitor that increases levels of active GLP‑1 and GIP, enhancing glucose‑dependent insulin secretion and reducing glucagon release, thereby lowering fasting and post‑prandial glucose with low hypoglycaemia risk.
Metformin hydrochloride 500 mg
Reduces hepatic glucose production, improves peripheral insulin sensitivity, and modestly promotes weight neutrality or mild weight loss; well‑established first‑line therapy in type 2 diabetes.
Main indications
Adjuvant to diet and exercise for improving glycaemic control in adults with type 2 diabetes who are not adequately controlled on metformin monotherapy.
Patients already on separate vildagliptin and metformin tablets, where switching to a fixed‑dose combination helps improve adherence.
Vermont M 50/500 can be positioned as a once‑dual‑mechanism, weight‑neutral‑oriented tablet suitable for diabetologists and physicians managing type 2 diabetes needing improved adherence and better HbA1c control without hypoglycaemia‑related burden
